Bayesian Capital Management, LP Esperion Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $103,424 - $154,624	51,200 New	51,200 $137,000
Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $16,896 - $31,504	17,600 New	17,600 $17,000
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $150,583 - $224,631	27,630 New	27,630 $185,000
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $142,122 - $198,732	-29,795 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $99,515 - $165,660	29,795 New	29,795 $138,000
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $115,803 - $244,403	-3,199 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $210,942 - $258,351	3,199 New	3,199 $231,000
Q4 2017 Feb 12, 2018	SELL	$43.47 - $67.43 $483,690 - $750,293	-11,127 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $487,362 - $587,171	11,127	11,127 $558,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $156M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.